

# **The value of $\alpha$ -Fetoprotein (AFP)-L3 and Transforming Growth Factor B1 (TGFB1) as Prognostic markers of Hepatocellular Carcinoma after Radiofrequency Ablation**

## *Thesis*

Submitted in Partial Fulfillment for the MD Degree  
*in Internal Medicine*

**By**

**Ahmed Jado Nabih**

*M. Sc. Medicine – Faculty of Medicine, Ain Shams University*

*Under the Supervision of*

**Prof. Dr. Ahmed Shawky Elsawaby**

*Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr. Khalid Abdelwahab**

*Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr. Wesam Ahmed Ibrahim**

*Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Dr. Shereen Abobakr Abdelrahman**

*Assistant Professor of Internal Medicine*

*Faculty of Medicine, Ain Shams University*

**Faculty of Medicine, Ain Shams University**

**2017**

# *List of Contents*

## *Page No.*

List of Figures .....	I
List of Tables .....	IV
List of Abbreviations .....	VII
Introduction .....	1
Aim of the Work .....	3
Hepatocellular carcinoma (HCC) .....	4
Percutaneous radio frequency ablation (RFA) .....	34
Alpha fetoprotein L3 (AFP) L3 .....	53
Transforming Growth Factor Beta1 (Tgfb1) .....	67
Subjects and Methods .....	80
Results .....	86
Discussion .....	124
Summary .....	137
Conclusion and Recommendations .....	143
References .....	145
Arabic Summary .....	—

## *List of Figures*

<b>Figure No.</b>	<b>Title</b>	<b>Page No.</b>
<b>Fig. (1):</b>	BCLC staging system and therapeutic strategy according to EASL–EORTC guidelines .....	16
<b>Fig.(2):</b>	Bar chart: the main complaint distribution among patient group .....	89
<b>Fig.(3):</b>	Pie chart tumor recurrence distribution of the patient group .....	92
<b>Fig.(4):</b>	Child-Pugh class distribution of the patient group .....	94
<b>Fig.(5):</b>	Bar chart between patients and control group regarding TGFB1, AFP and AFPL3/AFP% before radiofrequency ablation .....	96
<b>Fig.(6):</b>	Bar chart between patients and control regarding e of AFL3/AFP% [<10] before radiofrequency ablation .....	97
<b>Fig.(7):</b>	Bar chart between patients and control group after radiofrequency ablation .....	99
<b>Fig.(8):</b>	Bar chart between patients and control for AFPL3/AFP% [>10] after radiofrequency ablation .....	100

<b>Fig.(9):</b> Comparison regarding TGFB1, AFP and AFPL3/AFP% before and after radiofrequency ablation in patient group .....	102
<b>Fig.(10):</b> Bar chart between before and after radiofrequency ablation regarding to AFPL3/AFP% [ $>10$ ] .....	103
<b>Fig.(11):</b> Bar chart between before and after radiofrequency ablation in tumor recurrence group and no recurrence group .....	105
<b>Fig.(12):</b> Bar chart between tumor recurrence and AFPL3/AFP% in patients group .....	107
<b>Fig. (13):</b> Scatter plot between AFPL3/ AFP% and tumor recurrence in patients group .....	109
<b>Fig. (14):</b> Scatter plot between INR with TGFB1 pre and post .....	111
<b>Fig. (15):</b> Scatter plot between Total bilirubin with TGFB1 pre and post .....	112
<b>Fig. (16):</b> Scatter plot between albumin with TGFB1 pre and post .....	113
<b>Fig. (17):</b> Scatter plot between alkaline phosphatase with TGFB1 pre and post RFA .....	14
<b>Fig. (18):</b> Scatter plot between model for end-stage liver disease with TGFB1 pre and post .....	115

<b>Fig. (19):</b> Scatter plot between Child-Pugh class with TGFB1 pre and post .....	116
<b>Fig. (20):</b> Scatter plot between platelets count with TGFB1 pre and post .....	117
<b>Fig. (21):</b> Sensitivity and specificity within ROC curve in TGFB1, AFP and AFPL3/AFP in discrimination of patients and control .....	120
<b>Fig. (22):</b> Sensitivity and specificity within ROC curve in TGFB1, AFP and AFPL3/AFP in discrimination of tumour recurrence .....	122

## *List of Tables*

<b><i>Table No.</i></b>	<b><i>Title</i></b>	<b><i>Page No.</i></b>
<b>Table (1):</b>	Comparison between patients and control according to demographic data .....	87
<b>Table (2):</b>	The percentage of main complaint among the patients group (Group 1) .....	88
<b>Table (3):</b>	INR, Total bilirubin, Albumin, ALT, AST and Tumor size descriptive of the patients group .....	90
<b>Table (4):</b>	TGFB1, AFP and AFPL/AFP% before and after radiofrequency in patients group .....	91
<b>Table (5):</b>	Rate of tumor recurrence among the patients group .....	92
<b>Table (6):</b>	Alkaline phosphatase, Renal function and MESLD score, platelet count .....	93
<b>Table (7):</b>	Child-Pugh class distribution of the patients group .....	94
<b>Table (8):</b>	Comparison between patients and control group regarding TGFB1, AFP and AFPL3/AFP% before radiofrequency ablation .....	95

<b>Table (9):</b> Comparison between patients and control regarding TGFB1, AFP and AFPL3/AFP% after radiofrequency ablation .....	98
<b>Table (10):</b> Comparison regarding TGFB1, AFP and AFPL3/AFP% before and after radiofrequency ablation in patient group .....	101
<b>Table (11):</b> Difference between before and after radiofrequency ablation in tumor recurrence group and group with no tumor recurrence regarding TGFB1, AFP and AFPL3% .....	104
<b>Table (12):</b> Relation between tumor recurrence and AFPL3/AFP% in patients group .....	106
<b>Table (13):</b> Correlation between AFPL3/ AFP% and other parameters using Pearson Correlation Coefficient in patients group .....	108
<b>Table (14):</b> Correlation between TGFB1 and other parameters using Pearson Correlation Coefficient in patients group .....	110
<b>Table (15):</b> Correlation between TGFB1, AFP and AFL3/ AFP% using Pearson Correlation Coefficient in patients group .....	118
<b>Table (16):</b> Diagnostic Performance of after Radiofrequency Ablation in Discrimination of patients and control regarding TGFB1, AFP and AFPL3 .....	119

<b>Table (17):</b> Diagnostic Performance of after Radiofrequency Ablation in Discrimination of tumour recurrence regarding TGFB1, AFP and AFPL3/AFP% .....	121
--	-----

### *List of Abbreviations*

<b>3D-CRT</b>	3-dimensional conformal technique
<b>AASLD</b>	American Association of Study of the Liver Disease
<b>AFP</b>	Alpha fetoprotein
<b>AFPL3</b>	Alpha fetoprotein L3
<b>ALP</b>	Alkaline phosphatase
<b>ALT</b>	Alanine transaminase
<b>AST</b>	Aspartate transaminase
<b>BCLC</b>	Barcelona Clinic Liver Cancer
<b>BMI</b>	Body mass index
<b>CLD</b>	Chronic liver disease
<b>CLIP</b>	Cancer of the Liver Italian Program
<b>CT</b>	Computed tomography
<b>DAP-kinase1</b>	Death associated protein kinase1
<b>DAXX</b>	Death associated protein 6
<b>DCP</b>	Des-gamma-carboxy prothrombin
<b>DMD</b>	Duchenne muscular dystrophy
<b>EASL</b>	European Association of Study of Liver

<b>ECM</b>	Extracellular matrix
<b>EGFR</b>	Epidermal growth factor receptors
<b>GDP</b>	Guanosine 5 – Diphosphate
<b>GP 73</b>	Golgi protein-73
<b>HBV</b>	Hepatitis B virus
<b>HCC</b>	Hepatocellular carcinoma
<b>HCV</b>	Hepatitis C virus
<b>HIV</b>	Human immunodeficiency virus
<b>ILK</b>	Integrin-linked kinase
<b>INR</b>	International randomized ratio
<b>ITAS</b>	Micro total analysis system
<b>JIS</b>	Japan Integrate Staging
<b>LAP</b>	Latency associated peptide
<b>LCA</b>	Lens calinaris agglutinin
<b>MELD</b>	Model for End-Stage Liver Disease
<b>PEI</b>	Percutaneous ethanol injection
<b>PMCT</b>	Percutaneous microwave coagulation therapy
<b>POAG</b>	Primary open angle glaucoma
<b>PODs</b>	PML oncogenic domains

<b>RUQ</b>	Right upper quadrant
<b>SD</b>	Standard deviation
<b>Smads</b>	Mothers against decapentaplegic homolog
<b>SPSS</b>	Statistical Program for Social Science
<b>SVR</b>	Sustained virological response
<b>T Bilirubin</b>	Total bilirubin
<b>T.AFP</b>	Total alpha fetoprotein
<b>TACE</b>	Transarterial chemoembolization
<b>TbR</b>	TGFB1 receptor
<b>TNF-<math>\alpha</math></b>	Tumor necrosis factor-alpha
<b>U/S</b>	Ultrasound

## INTRODUCTION

Liver cancer in men is the fifth most frequently diagnosed cancer worldwide, and is the second leading cause of cancer-related death in the world. In women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death (**Jemal et al., 2011**).

Early detection of hepatocellular carcinoma (HCC) is important as the treatment of HCC with surgical resection, liver transplantation or percutaneous ablation can be curative at early stage (**Izumi, 2010**).

The recommended screening strategy for hepatocellular carcinoma includes measurement of serum  $\alpha$ -fetoprotein (AFP) levels and an abdominal ultrasound every 3-6 mo for the detection of HCC at an earlier stage (**Bruix and Sherman, 2011**). However, serum AFP level has a high false negative rate for the detection of small or early stage tumors (**Saffroy et al., 2007**) and it is often markedly elevated in patients with either cirrhosis or those with exacerbated chronic hepatitis without HCC (**Bae et al., 2005**).

AFP-L3 is an isoform of alphafetoprotein (AFP), has been reported to be highly specific for HCC (**Durazo et al., 2008**) and the surveillance program with this marker have

been mostly organized by Japanese study groups (**Izumi., 2010**).

TGF- $\beta$ 1 is a family of disulfide-linked polypeptides with a molecular weight of 25kD. There are three isoforms of TGF- $\beta$  expressed in mammals; TGF- $\beta$ -1, TGF- $\beta$ -2 and TGF- $\beta$ -3. Understanding the mechanism of TGF- $\beta$  has been the focus of recent studies in separating the pathogenesis of many human cancers (**Elliott and Blobe, 2005**).

TGF- $\beta$ -1 is the predominant and universally expressed isoform found in human liver. It has been implicated to play a role as a potent inhibitor of both normal and neoplastic rat hepatocyte proliferation as well as in the development of liver fibrosis. TGF- $\beta$ -1 has also been found to be elevated in serum, urine and tissues of patients with HCC (**Sacco et al., 2000**).

Radiofrequency ablation (RFA) is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60°C (**McGahan et al., 1992**). Radiofrequency ablation (RFA) has been used as the most popular method for treating early stage HCC and during the past two decades, many clinical studies have confirmed the safety and therapeutic efficacy of radiofrequency (**Yan et al., 2008**).

## **AIM OF THE WORK**

To asses the value of  $\alpha$ -fetoprotein (AFP)-L3 combined with transforming growth factor B1 (TGFB1) as prognostic markers in the hepatocellular carcinoma after radiofrequency.

# HEPATOCELLULAR CARCINOMA (HCC)

## Introduction

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor and is derived from hepatocytes. The most common causes are chronic viral infection (hepatitis B and C), aflatoxin B1 ingestion, and chronic alcoholic abuse (**Ayman Abdo et al., 2011**).

It is a fatal disease, with a life expectancy of about 6 months from the time of diagnosis and exhibits striking differences related to age, gender, ethnic group, and geographic region, and is rising even in countries with relatively low incidence (**Olivier Seror et al., 2014**).

It has poor prognosis and ranks third as the cause of cancer deaths in East Asia and sub-Saharan Africa and second as the cause of male cancer deaths in China. (**Yasunori Minami and Masatoshi Kudo, 2011**).

The majority of HCC patients present with an advanced stage for which chemotherapy and radiotherapy have limited efficacy (**Ryota Masuzaki and Masao Omata, 2008**).